• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血因子的调节。

The regulation of clotting factors.

作者信息

Kalafatis M, Egan J O, van 't Veer C, Cawthern K M, Mann K G

机构信息

Department of Biochemistry, University of Vermont, College of Medicine, Burlington 05405-0068, USA.

出版信息

Crit Rev Eukaryot Gene Expr. 1997;7(3):241-80. doi: 10.1615/critreveukargeneexpr.v7.i3.40.

DOI:10.1615/critreveukargeneexpr.v7.i3.40
PMID:9399073
Abstract

Blood clotting involves a multitude of proteins that act in concert in response to vascular injury to produce the procoagulant enzyme alpha-thrombin, which in turn is responsible for the generation of the fibrin plug. However, while generation of the fibrin plug is required for the arrest of excessive bleeding, unregulated clotting will result in the occlusion of the blood vessels and thrombosis. Thus, the regulation of the delicate balance between the procoagulant and anticoagulant mechanisms is of extreme importance for survival. While the majority of proteins involved in blood coagulation circulate as inactive zymogens that require proteolytic activation in order to function, approximately 1% of the circulating factor VII molecules are active. Factor VIIa, possess a serine protease active site, has poor catalytic activity, and is not inhibited by the circulating stoichiometric protease inhibitors. Following injury to the vasculature and subsequent exposure of the integral membrane glycoprotein, tissue factor (TF), the circulating factor VIIa molecules can bind to the exposed TF forming the extrinsic tenase complex (TF/factor VIIa) and initiate the blood coagulation process. Formation of the TF/factor VIIa complex increases the catalytic efficiency of the enzyme by four orders of magnitude when compared with factor VIIa alone. This cell-associated enzymatic complex initiates a series of enzymatic reactions, leading to the generation of alpha-thrombin and ultimately to the formation of the fibrin plug. The procoagulant enzymatic complexes (i.e., prothrombinase, intrinsic tenase, and extrinsic tenase) are similar in structure and composed of an enzyme, a cofactor, and the substrate associated on a cell surface in the presence of divalent metal ions. While the activity of the extrinsic tenase complex is limited by the availability (exposure) of its cell-associated cofactor (TF) it is remarkable that the activities of both the prothrombinase complex (factor Va/factor Xa) as well as the intrinsic tenase complex (factor VIIIa/factor IXa) are limited by the presence of the two soluble, nonenzymatic cofactors, factor Va and factor VIIIa. Factor Va and factor VIIIa, which are very similar in structure and function, are required for prothrombinase and intrinsic tenase activities, respectively, because both cofactors express a dual function in their respective complexes, acting as an enzyme receptor and catalytic effector on the cell surface. The cofactors derive from inactive plasma precursors by regulatory proteolytic events that involve alpha-thrombin. In general, bleeding tendencies are usually associated with defects in the activation of one of the zymogens or the cofactors of the procoagulant complexes. However, the activity of all of the complexes is also limited by the availability of an adequate membrane surface provided by endothelial cells, platelets, and monocytes. The cell surface provides a site for the recruitment of the appropriate proteins and allows for fast and efficient clot formation. In the absence of an appropriate membrane surface, the procoagulant complexes have limited catalytic efficiency. Thus, timely exposure of the adequate membrane surface is an additional step in the regulation of alpha-thrombin formation. alpha-Thrombin participates in its own down-regulation by binding to the endothelial cell receptor thrombomodulin, initiating the protein C pathway, which in turn leads to the formation of activated protein C (APC). APC is required for efficient neutralization of factor Va cofactor activity, which results in the inactivation of the prothrombin-activating complex. This inactivation can only occur in the presence of the appropriate membrane surface. Thus, while following alpha-thrombin activation, factor VIIIa is rapidly and spontaneously inactivated by dissociation of the A2 domain from the rest of the cofactor, APC is required for down-regulation of alpha-thrombin formation by prothrombinase. (ABSTRACT

摘要

血液凝固涉及多种蛋白质,这些蛋白质在血管损伤时协同作用,产生促凝血酶α-凝血酶,而α-凝血酶又负责纤维蛋白凝块的形成。然而,虽然形成纤维蛋白凝块是阻止过度出血所必需的,但不受控制的凝血会导致血管阻塞和血栓形成。因此,调节促凝血和抗凝血机制之间的微妙平衡对生存至关重要。虽然参与血液凝固的大多数蛋白质以无活性的酶原形式循环,需要蛋白水解激活才能发挥作用,但循环中的因子VII分子约有1%是有活性的。具有丝氨酸蛋白酶活性位点的因子VIIa催化活性较差,且不受循环中的化学计量蛋白酶抑制剂的抑制。血管受损以及随后整合膜糖蛋白组织因子(TF)暴露后,循环中的因子VIIa分子可与暴露的TF结合,形成外源性凝血酶原酶复合物(TF/因子VIIa),并启动血液凝固过程。与单独的因子VIIa相比,TF/因子VIIa复合物的形成使酶的催化效率提高了四个数量级。这种细胞相关的酶复合物引发一系列酶促反应,导致α-凝血酶的产生,并最终形成纤维蛋白凝块。促凝血酶复合物(即凝血酶原酶、内源性凝血酶原酶和外源性凝血酶原酶)结构相似,由一种酶、一种辅因子和在二价金属离子存在下与细胞表面结合的底物组成。虽然外源性凝血酶原酶复合物的活性受其细胞相关辅因子(TF)可用性(暴露程度)的限制,但值得注意的是,凝血酶原酶复合物(因子Va/因子Xa)和内源性凝血酶原酶复合物(因子VIIIa/因子IXa)的活性均受两种可溶性非酶辅因子因子Va和因子VIIIa的存在的限制。结构和功能非常相似的因子Va和因子VIIIa分别是凝血酶原酶和内源性凝血酶原酶活性所必需的,因为这两种辅因子在各自的复合物中都发挥双重作用,在细胞表面充当酶受体和催化效应物。这些辅因子通过涉及α-凝血酶的调节性蛋白水解事件从无活性的血浆前体衍生而来。一般来说,出血倾向通常与促凝血复合物的一种酶原或辅因子激活缺陷有关。然而,所有复合物的活性也受内皮细胞、血小板和单核细胞提供的足够膜表面可用性的限制。细胞表面为募集合适的蛋白质提供了一个位点,并允许快速有效地形成凝块。在没有合适的膜表面时,促凝血复合物的催化效率有限。因此,及时暴露足够的膜表面是调节α-凝血酶形成的另一个步骤。α-凝血酶通过与内皮细胞受体血栓调节蛋白结合参与自身的下调,启动蛋白C途径,进而导致活化蛋白C(APC)的形成。APC是有效中和因子Va辅因子活性所必需的,这会导致凝血酶原激活复合物失活。这种失活只能在存在合适的膜表面时发生。因此,虽然在α-凝血酶激活后,因子VIIIa会通过A2结构域与辅因子其余部分解离而迅速自发失活,但APC是凝血酶原酶下调α-凝血酶形成所必需的。(摘要)

相似文献

1
The regulation of clotting factors.凝血因子的调节。
Crit Rev Eukaryot Gene Expr. 1997;7(3):241-80. doi: 10.1615/critreveukargeneexpr.v7.i3.40.
2
Factor V: Dr. Jeckyll and Mr. Hyde.凝血因子V:ekyll博士与Hyde先生。 (注:这里Dr. Jeckyll and Mr. Hyde是英国小说《化身博士》中的人物,有善恶双重人格的寓意 ,在医学领域常用来类比凝血因子V的复杂特性 )
Adv Exp Med Biol. 2001;489:31-43. doi: 10.1007/978-1-4615-1277-6_3.
3
Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.纤维蛋白凝块的形成:促凝血因子与抑制因子的平衡。
Clin Haematol. 1985 Jun;14(2):281-342.
4
Tissue factor pathway.组织因子途径。
Baillieres Clin Haematol. 1994 Sep;7(3):469-84. doi: 10.1016/s0950-3536(05)80094-0.
5
Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II.组织因子途径抑制物、抗凝血酶III和肝素辅因子II等化学计量抑制剂对组织因子启动的凝血酶生成的调节作用。
J Biol Chem. 1997 Feb 14;272(7):4367-77. doi: 10.1074/jbc.272.7.4367.
6
Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin.原位生成的凝血酶原激活产物在内皮细胞上激活蛋白C:中间凝血酶比α-凝血酶是更好的蛋白C激活剂。
Biochem J. 1996 Oct 15;319 ( Pt 2)(Pt 2):399-405. doi: 10.1042/bj3190399.
7
Factor V Deficiency因子V缺乏症
8
Mechanisms that regulate the anticoagulant function of coagulation factor V.调节凝血因子V抗凝功能的机制。
Scand J Clin Lab Invest Suppl. 1999;229:19-26. doi: 10.1080/00365519950185913.
9
Factor VIIa-mediated tenase function on activated platelets under flow.凝血因子VIIa在流动状态下对活化血小板的凝血酶原酶功能。
J Thromb Haemost. 2004 Aug;2(8):1402-10. doi: 10.1111/j.1538-7836.2004.00828.x.
10
Platelet procoagulant complex assembly in a tissue factor-initiated system.组织因子启动系统中血小板促凝复合物的组装
Br J Haematol. 1994 Oct;88(2):364-71. doi: 10.1111/j.1365-2141.1994.tb05032.x.

引用本文的文献

1
Surface Engineering of Bioactive Coatings for Improved Stent Hemocompatibility: A Comprehensive Review.用于改善支架血液相容性的生物活性涂层的表面工程:综述
Materials (Basel). 2023 Oct 29;16(21):6940. doi: 10.3390/ma16216940.
2
Screening of proteases produced by micromycetes active against proteins of the hemostasis system.对能够作用于止血系统蛋白质的微真菌所产生的蛋白酶进行筛选。
Curr Med Mycol. 2023 Mar;9(1):8-13. doi: 10.18502/CMM.2023.150674.
3
Bioactive Natural Compounds with Antiplatelet and Anticoagulant Activity and Their Potential Role in the Treatment of Thrombotic Disorders.
具有抗血小板和抗凝活性的生物活性天然化合物及其在血栓性疾病治疗中的潜在作用
Life (Basel). 2021 Oct 15;11(10):1095. doi: 10.3390/life11101095.
4
Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa.以其人之道还治其人之身:可溶性非组织因子依赖的凝血因子VIIa的设计与特性
J Biol Chem. 2020 Jan 10;295(2):517-528. doi: 10.1074/jbc.RA119.009183. Epub 2019 Dec 4.
5
Exploring the molecular complexity of Triatoma dimidiata sialome.探索 Triatoma dimidiata 唾液腺的分子复杂性。
J Proteomics. 2018 Mar 1;174:47-60. doi: 10.1016/j.jprot.2017.12.016. Epub 2017 Dec 27.
6
Spellbinding Effects of the Acidic COOH-Terminus of Factor Va Heavy Chain on Prothrombinase Activity and Function.凝血因子Va重链酸性COOH末端对凝血酶原酶活性和功能的迷人作用。
ACS Omega. 2017 Sep 30;2(9):5529-5537. doi: 10.1021/acsomega.7b00769. Epub 2017 Sep 6.
7
A Deep Insight into the Sialome of Rhodnius neglectus, a Vector of Chagas Disease.深入了解克氏锥虫病传播媒介——忽视罗蛉的唾液蛋白质组
PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004581. doi: 10.1371/journal.pntd.0004581. eCollection 2016 Apr.
8
Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.(超级)因子Va的安全性、稳定性及药代动力学特性,一种用于治疗严重出血的新型工程凝血因子V
Pharm Res. 2016 Jun;33(6):1517-26. doi: 10.1007/s11095-016-1895-3. Epub 2016 Mar 9.
9
The Dual Regulatory Role of Amino Acids Leu480 and Gln481 of Prothrombin.凝血酶原中亮氨酸480和谷氨酰胺481氨基酸的双重调节作用
J Biol Chem. 2016 Jan 22;291(4):1565-1581. doi: 10.1074/jbc.M115.691956. Epub 2015 Nov 24.
10
Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.通过超因子Va和因子VIIa联合使用改善血友病伴抑制剂患者的凝血和止血功能。
Thromb Haemost. 2016 Mar;115(3):551-61. doi: 10.1160/TH15-07-0525. Epub 2015 Oct 15.